← ANALYST RATINGS · TIPRANKS
Starling Oncology Institute (STLN): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $10.00, the highest $11.00, the lowest $9.00. The average is +55.5% from the last price of $6.43.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Matthew Shea★★★★★★★★★★#6280 · hits 52% · avg +3.4% | Needham | $7.00 → $9.00+28.6% | Buy | +40.0% | Reiterated | 14.10.26on TipRanks 07:30 | −1.8%next day +5.9% | ↗ |
| AI xAi Medical - Care FacilitiesxAI Grok-4 | TipRanks - xAI | $7.00 | Hold | +8.9% | Reiterated | 22.08.26on TipRanks 00:05 | — | |
| AI DeepSeek Medical - Care FacilitiesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $6.50 | Hold | +1.1% | Reiterated | 22.08.26on TipRanks 00:05 | — | |
| AI OpenAI Medical - Care FacilitiesOpenAI 5.2 | TipRanks - OpenAI | $6.50 → $7.00+7.7% | Hold | +8.9% | Reiterated | 22.08.26on TipRanks 00:05 | — | |
| AI Anthropic Medical - Care FacilitiesAnthropic Opus-4.6 | TipRanks - Anthropic | $6.50 → $7.00+7.7% | Hold | +8.9% | Reiterated | 22.08.26on TipRanks 00:05 | — | |
| AI Google Medical - Care FacilitiesGemini 3.1Pro | TipRanks - Google | $7.00 | Hold | +8.9% | Reiterated | 22.08.26on TipRanks 00:05 | — | |
| AI PerPlexity Medical - Care FacilitiesPerPlexity SonarPro | TipRanks - PerPlexity | $6.50 → $7.00+7.7% | Hold | +8.9% | Reiterated | 22.08.26on TipRanks 00:05 | — | |
| Matthew Shea★★★★★★★★★★#6280 · hits 52% · avg +3.4% | Needham | $7.00 | Buy | +8.9% | Reiterated | 07.08.26on TipRanks 11:12 | +27.8%next day −3.9% · 5 days +0.2% | ↗ |
| Yuan Zhi★★★★★★★★★★#1180 · hits 41% · avg +20.7% | B. Riley Securities | $8.00 → $11.00+37.5% | Buy | +71.1% | Reiterated | 07.08.26on TipRanks 08:50 | +27.8%next day −3.9% · 5 days +0.2% | ↗ |
| David Larsen★★★★★★★★★★#12072 · hits 35% · avg −4.7% | BTIG | $8.00 → $9.00+12.5% | Buy | +40.0% | Reiterated | 15.07.26on TipRanks Aug 7 08:50 | −10.3%next day −6.5% · 5 days −5.6% | ↗ |
| Ben Haynor★★★★★★★★★★#11216 · hits 35% · avg −2.8% | Lake Street | $10.00 | Buy | +55.5% | Initiated | 06.07.26on TipRanks Aug 7 08:50 | +2.2%next day +7.1% · 5 days +15.2% | ↗ |
| Robert LeBoyer★★★★★★★★★★#12335 · hits 27% · avg −14.2% | Noble Financial | $8.00 | Buy | +24.4% | Reiterated | 08.05.26on TipRanks Aug 7 08:50 | −2.5%next day 0.0% · 5 days −0.7% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Starling Oncology Institute
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $9.25 at a price of $6.32 (+46.4%); now: $10.00 at $6.43 (+55.5%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 4 | 6 | 5 | 4 | 1 |
| Buy | 2 | 3 | 3 | 4 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.05 (from $-0.07 to $-0.04). Last quarter: $-0.08.
Sales
Next quarter’s sales estimate — $169M (from $165M to $172M). Last quarter: $161M.
Best top-analyst consensus in the sector · Healthcare
About Starling Oncology Institute
- CEO: Daniel Virnich
- Employees: 641
- 18000 Studebaker Road, Suite 800, Cerritos, CA, 90703, US
- www.starlingoncology.com
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
Data from the stock’s TipRanks forecast page, read 28 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗